These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9157098)

  • 21. Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study.
    Ricketts EJ; Sturm A; McMakin DL; McGuire JF; Tan PZ; Smalberg FB; McCracken JT; Colwell CS; Piacentini J
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):690-698. PubMed ID: 30388029
    [No Abstract]   [Full Text] [Related]  

  • 22. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Methylphenidate double-blind trial: indication and performing].
    Bliznakova L; Gerstner S; Schmidt MH; Becker K
    Klin Padiatr; 2007; 219(1):9-16. PubMed ID: 17205427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Attention deficit hyperactivity syndrome (ADHS) in Germany].
    Schlander M
    Krankenpfl J; 2004; 42(5-6):152. PubMed ID: 15527216
    [No Abstract]   [Full Text] [Related]  

  • 25. Behavior modification.
    Pelham WE; Fabiano GA
    Child Adolesc Psychiatr Clin N Am; 2000 Jul; 9(3):671-88, ix. PubMed ID: 10944662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder.
    Rader R; McCauley L; Callen EC
    Am Fam Physician; 2009 Apr; 79(8):657-65. PubMed ID: 19405409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.
    Swanson J; Gupta S; Guinta D; Flynn D; Agler D; Lerner M; Williams L; Shoulson I; Wigal S
    Clin Pharmacol Ther; 1999 Sep; 66(3):295-305. PubMed ID: 10511066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The management of patients with attention-deficit hyperactivity disorder by family practitioners.
    Eppright TD; Bradley S; Vogel SJ; Williamson HA
    Mo Med; 1998 Mar; 95(3):118-22. PubMed ID: 9529896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylphenidate compared with behavioral self-control in attention deficit disorder: preliminary report.
    Anderson EE; Clement PW; Oettinger L
    J Dev Behav Pediatr; 1981 Dec; 2(4):137-41. PubMed ID: 7320203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylphenidate and attentional training. Comparative effects on behavior and neurocognitive performance in twin girls with attention-deficit/hyperactivity disorder.
    Rapport MD; Loo S; Isaacs P; Goya S; Denney C; Scanlan S
    Behav Modif; 1996 Oct; 20(4):428-30. PubMed ID: 8875814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attention-deficit hyperactivity disorders in adolescence.
    Wender EH
    J Dev Behav Pediatr; 1995 Jun; 16(3):192-5. PubMed ID: 7560123
    [No Abstract]   [Full Text] [Related]  

  • 34. Stimulants and neuroleptic withdrawal dyskinesia.
    Connor DF
    J Am Acad Child Adolesc Psychiatry; 1998 Mar; 37(3):247-8. PubMed ID: 9519625
    [No Abstract]   [Full Text] [Related]  

  • 35. Development of clinical services for attention-deficit/hyperactivity disorder.
    Taylor E
    Arch Gen Psychiatry; 1999 Dec; 56(12):1097-9. PubMed ID: 10591285
    [No Abstract]   [Full Text] [Related]  

  • 36. Acute generalized exanthematous pustulosis induced by methylphenidate: a new adverse effect.
    Heinzerling LM; Pichler W; Anliker MD
    Arch Dermatol; 2011 Jul; 147(7):872-3. PubMed ID: 21768498
    [No Abstract]   [Full Text] [Related]  

  • 37. Longer term effects of stimulant treatments for Attention-Deficit/Hyperactivity Disorder.
    Jensen P
    J Atten Disord; 2002; 6 Suppl 1():S45-56. PubMed ID: 12685518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The most effective intervention for attention deficit-hyperactivity disorder: using continuous performance test.
    Meftagh SD; Najimi A; Mohammadi N; Ghanizadeh A; Rahimi C; Amini MM
    Psychiatr Danub; 2014 Jun; 26(2):165-71. PubMed ID: 24909254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents.
    Feldman HM; Reiff MI
    N Engl J Med; 2014 Feb; 370(9):838-46. PubMed ID: 24571756
    [No Abstract]   [Full Text] [Related]  

  • 40. Beyond "real boys" and back to parental obligations.
    Hughes J
    Am J Bioeth; 2005; 5(3):61-2; discussion W10-2. PubMed ID: 16006373
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.